Journal of Pharma and Drug Innovation

Frequency : Bi-Annual (Two issues per year)
Editorial & Review Timeline
3 - 6 Days Initial Quality Review
30 Days Peer Evaluation Summary
45 - 60 Days Complete Editorial Processing Time

Dr Xiaona Wang

Ph.D

  • Affiliation: Associate Professor
  • Department: Henan Key Laboratory of Childrens Genetics and Metabolic Diseases
  • University: Zhengzhou University
  • Email: xiaonawang2015@163.com
  • Country: China

Dr. Xiaona Wang is an Associate Professor in the Henan Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University. She obtained her Ph.D. in Neurobiology from Shandong University in 2016 and completed postdoctoral training at Indiana University-Purdue University Indianapolis in 2017. Her research focuses on neurodevelopmental disorders, autism spectrum disorder, epilepsy, intellectual disability, and the neuroprotective effects of drugs against neurological diseases.

She has served as Principal Investigator for projects funded by the National Natural Science Foundation of China and provincial research programs. Dr. Wang has published numerous SCI-indexed articles in high-impact journals and serves as Youth Editor, Academic Editor, Guest Editor, and reviewer for several international journals in pharmacology, neuroscience, and translational medicine.

  • Youth Editor: Clinical and Experimental Pharmacology and Physiology
  • Youth Editor: Current Molecular Pharmacology
  • Youth Editor: Neuropharmacology and Therapy
  • Academic Editor: PLoS One
  • Guest Editor: Frontiers in Psychiatry
  • Reviewer for Molecular Autism, Molecular Neurobiology, Expert Review of Neurotherapeutics, Current Molecular Pharmacology, Expert Opinion on Drug Safety, CNS & Neurological Disorders Drug Targets, and many other journals.
  • Principal Investigator of National Natural Science Foundation of China projects.
  • Holder of multiple Chinese invention patents related to autism therapeutics and biomarkers.
  • Award recipient for several provincial scientific achievement awards.

  • Ertugliflozin improves animal behaviours associated with oxidative stress and inflammation in a BTBR mouse model of autism. Brain Communications, 2026.
  • Somatostatin-expressing interneurons of prefrontal cortex modulate social deficits in the Magel2 mouse model of autism. Molecular Autism, 2025.
  • Restoration of nNOS expression rescues autistic-like phenotypes through normalization of AMPA receptor-mediated neurotransmission. Molecular Neurobiology, 2024.
  • Neuroprotective effects of CXCR2 antagonist SB332235 on traumatic brain injury through suppressing NLRP3 inflammasome. Neurochemical Research, 2024.
  • GABAB1 receptor knockdown in prefrontal cortex induces behavioral aberrations associated with autism spectrum disorder in mice. Brain Research Bulletin, 2023.
  • Functional evaluation of a novel GRIN2B missense variant associated with epilepsy and intellectual disability. Neuroscience, 2023.
  • The GluN2B-Trp373 NMDA receptor variant is associated with autism- and epilepsy-related phenotypes and reduces NMDA receptor currents in rats. Neurochemical Research, 2022.
  • Overexpression of mGluR7 in the prefrontal cortex attenuates autistic behaviors in mice. Frontiers in Cellular Neuroscience, 2021.
  • Gastrodin rescues autistic-like phenotypes in valproic acid-induced animal model. Frontiers in Neurology, 2018.